# Hoffmann-La Roche: Phase 3 study started recruiting, 400 planned (Non-small Cell Lung Cancer)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) |
| NCT ID | NCT07541170 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Non-small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 400 |
| Site countries | United States, Argentina, Brazil, Canada, China, Colombia, Greece, Hong Kong, Italy, Japan, Poland, Portugal |
| Posted | 2026-04-21 |
| Planned start | 2026-10-06 |
| Event | Started recruiting |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 400 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07541170). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.